Cinitapride

DB08810InvestigationalSmall molecule

Cinitapride is a benzamide with gastroprokinetic and antiemetic properties typically used for the treatment of gastrointestinal motility disorders such as gastroesophageal reflux disease (GERD), non-ulcer dyspepsia, and delayed gastric emptying. Cinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors.

Chemical structure of Cinitapride
Mechanism
Curator reviewed
Primary indication
It is indicated to treat gastrointestinal disorders associated with motility disturbances like gastroesophageal reflux disease (GERD), non-ulcer dyspepsia and delayed gastric emptying.Curator reviewed · 8 structured indications
Formula / weight
C21H30N4O4 · 402.4873 g/mol (avg)

Resolves to

Compound
UNIIR8I97I2L24CAS66564-14-5ChEMBLCHEMBL2104523ChEBI135642PubChem68867KEGGD07700
Clinical / RWD
RxNorm21125ATCA03FA08PharmGKBPA165958427
Structure
InChIKeyZDLBNXXKDMLZMF-UHFFFAOYSA-NSMILESCCOC1=CC(N)=C(C=C1C(=O)NC1CCN(CC2CCC=CC2)CC1)[N+]([O-])=O
Targets
P08908HTR1AP28223HTR2AQ13639HTR4

What you can answer from here — as of August 30, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,079Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
8Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
23ContraindicationsEach with its own population and attribute set
Sign in
10Marketed productsAcross 1 country and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 19 drug categories
Sign in
7+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Cinitapride, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In